Syntekabio Showcases AI Drug Discovery Innovations at UKC 2022

Syntekabio will present its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference (UKC) 2022 in Arlington, Virginia on August 19. Led by Dr. Kilyoung Kim, the presentation aims to showcase innovative advancements to enhance drug development. Attendees can explore networking opportunities as the conference promotes US-Korea collaboration in science and entrepreneurship.

Syntekabio, a global leader in AI-driven drug discovery and development, is poised to showcase its pioneering cloud platforms, DeepMatcher® and NEO-ARS™, at the upcoming US-Korea Conference (UKC) 2022. This significant event will take place on August 19 in Arlington, Virginia, where Dr. Kilyoung Kim, Chief Scientific Officer and President of Syntekabio USA, will present these innovative technologies. The launch of these platforms is scheduled for September, marking a substantial advancement in the field of pharmaceutical research and development.

The UKC serves as a collaborative forum for American and Korean professionals engaged in science, engineering, technology, and entrepreneurship. By fostering cooperation and networking opportunities, the conference aims to inspire aspiring entrepreneurs, allowing them to connect with esteemed industry leaders and investors. The Innovative and Entrepreneurship Symposium (IES) is particularly noteworthy, as it provides participating entities a stage to share their insights and contribute to cross-border business collaborations. More information regarding the event can be found at https://ukc.ksea.org/ukc2022/.

Dr. Kilyoung Kim’s presentation will cover the transformative capabilities of Syntekabio’s AI platforms in drug discovery. This company, with its headquarters in South Korea since 2009, operates in the U.S. to deliver cutting-edge technologies that align with international standards for developing medicines that aim to combat diseases and enhance public health. Media members will have the opportunity to engage with Syntekabio’s leadership following the presentation to further explore the company’s contributions to the healthcare sector.

The integration of artificial intelligence in drug discovery represents a revolutionary shift in the pharmaceutical industry. Companies like Syntekabio are at the forefront of this movement, leveraging AI to enhance the efficiency and accuracy of drug development processes. By utilizing cloud technology, platforms such as DeepMatcher® and NEO-ARS™ aim to optimize research and streamline the workflow, ultimately leading to the discovery of new and effective treatments. The UKC provides a vital platform for showcasing such innovations.

In summary, Syntekabio’s participation in the UKC 2022 highlights the company’s commitment to advancing AI-driven drug discovery. The introduction of its proprietary platforms, DeepMatcher® and NEO-ARS™, signifies a meaningful contribution to the pharmaceutical landscape. The collaborative environment fostered by the UKC serves as a valuable opportunity for knowledge sharing and networking among professionals seeking to drive innovation in science and technology.

Original Source: www.globenewswire.com